Concepts (190)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Status Epilepticus | 11 | 2024 | 14 | 4.480 |
Why?
|
| Seizures | 8 | 2022 | 33 | 3.460 |
Why?
|
| Brain Injuries, Traumatic | 5 | 2024 | 45 | 3.190 |
Why?
|
| Electroencephalography | 18 | 2024 | 134 | 3.140 |
Why?
|
| Coma | 5 | 2024 | 8 | 2.640 |
Why?
|
| Recovery of Function | 3 | 2024 | 21 | 2.260 |
Why?
|
| Humans | 56 | 2025 | 5476 | 2.160 |
Why?
|
| Cerebral Hemorrhage | 5 | 2023 | 5 | 2.140 |
Why?
|
| Stroke | 6 | 2023 | 53 | 2.050 |
Why?
|
| Consciousness Disorders | 5 | 2023 | 8 | 1.870 |
Why?
|
| Aged | 23 | 2024 | 859 | 1.770 |
Why?
|
| Middle Aged | 25 | 2025 | 1098 | 1.750 |
Why?
|
| Brain Injuries | 4 | 2023 | 31 | 1.720 |
Why?
|
| Brain | 8 | 2024 | 286 | 1.630 |
Why?
|
| Female | 29 | 2025 | 2811 | 1.570 |
Why?
|
| Subarachnoid Hemorrhage | 6 | 2022 | 6 | 1.450 |
Why?
|
| Male | 25 | 2025 | 2765 | 1.340 |
Why?
|
| Brain Ischemia | 5 | 2023 | 8 | 1.330 |
Why?
|
| Critical Care | 4 | 2022 | 12 | 1.270 |
Why?
|
| Intensive Care Units | 6 | 2023 | 17 | 1.200 |
Why?
|
| Consciousness | 6 | 2024 | 12 | 1.060 |
Why?
|
| Drug Resistant Epilepsy | 3 | 2023 | 10 | 1.050 |
Why?
|
| Retrospective Studies | 13 | 2024 | 382 | 1.030 |
Why?
|
| Registries | 6 | 2025 | 24 | 0.960 |
Why?
|
| Ketamine | 2 | 2024 | 4 | 0.900 |
Why?
|
| Hospitalization | 1 | 2024 | 38 | 0.890 |
Why?
|
| Aged, 80 and over | 10 | 2024 | 320 | 0.870 |
Why?
|
| Anticonvulsants | 3 | 2020 | 6 | 0.870 |
Why?
|
| Severity of Illness Index | 4 | 2024 | 71 | 0.840 |
Why?
|
| Cognitive Dysfunction | 1 | 2024 | 66 | 0.830 |
Why?
|
| Neuropsychological Tests | 1 | 2024 | 176 | 0.820 |
Why?
|
| Biomarkers | 2 | 2020 | 87 | 0.760 |
Why?
|
| Withholding Treatment | 1 | 2021 | 6 | 0.740 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2023 | 63 | 0.730 |
Why?
|
| Inflammation Mediators | 1 | 2020 | 10 | 0.680 |
Why?
|
| Adult | 12 | 2025 | 1683 | 0.670 |
Why?
|
| Amantadine | 1 | 2020 | 1 | 0.670 |
Why?
|
| Dopamine Agents | 1 | 2020 | 2 | 0.670 |
Why?
|
| Hyperemia | 1 | 2019 | 4 | 0.630 |
Why?
|
| Troponin | 1 | 2019 | 1 | 0.630 |
Why?
|
| Myocardial Infarction | 1 | 2019 | 11 | 0.620 |
Why?
|
| Triage | 2 | 2021 | 2 | 0.610 |
Why?
|
| Risk Factors | 7 | 2025 | 184 | 0.600 |
Why?
|
| Liver Diseases | 1 | 2018 | 3 | 0.590 |
Why?
|
| Periodicity | 1 | 2018 | 2 | 0.580 |
Why?
|
| Heart Arrest | 3 | 2024 | 5 | 0.580 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 11 | 0.580 |
Why?
|
| Brain Waves | 1 | 2018 | 7 | 0.580 |
Why?
|
| Patient Admission | 1 | 2017 | 1 | 0.560 |
Why?
|
| Ischemic Attack, Transient | 1 | 2017 | 1 | 0.540 |
Why?
|
| Hematoma, Subdural, Chronic | 1 | 2017 | 1 | 0.540 |
Why?
|
| Prospective Studies | 6 | 2025 | 132 | 0.510 |
Why?
|
| Behcet Syndrome | 1 | 2016 | 1 | 0.510 |
Why?
|
| Hyperventilation | 1 | 2016 | 1 | 0.510 |
Why?
|
| Brain Diseases | 1 | 2016 | 4 | 0.500 |
Why?
|
| Mucopolysaccharidosis II | 1 | 2015 | 1 | 0.500 |
Why?
|
| Ultrasonography, Doppler | 1 | 2015 | 1 | 0.500 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 2015 | 5 | 0.490 |
Why?
|
| Time-to-Treatment | 2 | 2024 | 4 | 0.440 |
Why?
|
| Hospital Mortality | 3 | 2023 | 9 | 0.430 |
Why?
|
| Prognosis | 3 | 2023 | 59 | 0.420 |
Why?
|
| Patient Discharge | 2 | 2023 | 17 | 0.380 |
Why?
|
| Cross-Sectional Studies | 3 | 2024 | 284 | 0.380 |
Why?
|
| Hypertension | 3 | 2025 | 61 | 0.370 |
Why?
|
| Treatment Outcome | 5 | 2024 | 212 | 0.360 |
Why?
|
| Electroconvulsive Therapy | 2 | 2023 | 2 | 0.350 |
Why?
|
| Intracranial Pressure | 2 | 2021 | 6 | 0.330 |
Why?
|
| Florida | 6 | 2025 | 9 | 0.320 |
Why?
|
| Machine Learning | 2 | 2021 | 39 | 0.320 |
Why?
|
| Young Adult | 3 | 2025 | 850 | 0.310 |
Why?
|
| Cerebrovascular Circulation | 2 | 2019 | 8 | 0.290 |
Why?
|
| Thrombolytic Therapy | 2 | 2024 | 2 | 0.280 |
Why?
|
| Clinical Competence | 2 | 2023 | 14 | 0.260 |
Why?
|
| Cluster Analysis | 2 | 2023 | 25 | 0.260 |
Why?
|
| Data Collection | 2 | 2023 | 15 | 0.240 |
Why?
|
| Certification | 2 | 2023 | 4 | 0.240 |
Why?
|
| Length of Stay | 2 | 2021 | 7 | 0.230 |
Why?
|
| Blood Pressure | 2 | 2023 | 40 | 0.230 |
Why?
|
| Glasgow Coma Scale | 2 | 2021 | 2 | 0.220 |
Why?
|
| Neurophysiological Monitoring | 2 | 2021 | 2 | 0.220 |
Why?
|
| Guideline Adherence | 1 | 2023 | 6 | 0.220 |
Why?
|
| Common Data Elements | 1 | 2023 | 3 | 0.210 |
Why?
|
| Antihypertensive Agents | 1 | 2023 | 16 | 0.210 |
Why?
|
| Paresthesia | 1 | 2023 | 1 | 0.210 |
Why?
|
| Biomedical Research | 1 | 2023 | 12 | 0.210 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2023 | 1 | 0.210 |
Why?
|
| Physical Examination | 1 | 2023 | 7 | 0.210 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2023 | 47 | 0.210 |
Why?
|
| Delirium | 1 | 2023 | 7 | 0.210 |
Why?
|
| Punctures | 1 | 2023 | 2 | 0.200 |
Why?
|
| Aftercare | 1 | 2023 | 6 | 0.200 |
Why?
|
| Survivors | 1 | 2023 | 17 | 0.200 |
Why?
|
| Vision Disorders | 1 | 2023 | 44 | 0.200 |
Why?
|
| Epilepsy, Post-Traumatic | 1 | 2022 | 1 | 0.200 |
Why?
|
| Hydrocephalus | 1 | 2022 | 18 | 0.190 |
Why?
|
| Cohort Studies | 2 | 2023 | 131 | 0.190 |
Why?
|
| Resuscitation Orders | 1 | 2021 | 1 | 0.190 |
Why?
|
| Brain Diseases, Metabolic | 1 | 2021 | 1 | 0.190 |
Why?
|
| Benzodiazepines | 2 | 2021 | 13 | 0.180 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2021 | 1 | 0.180 |
Why?
|
| Cerebral Intraventricular Hemorrhage | 1 | 2021 | 1 | 0.180 |
Why?
|
| Prone Position | 1 | 2021 | 1 | 0.180 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 6 | 0.180 |
Why?
|
| Cerebral Ventriculitis | 1 | 2021 | 2 | 0.180 |
Why?
|
| Physicians | 1 | 2021 | 18 | 0.170 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 5 | 0.170 |
Why?
|
| Forecasting | 1 | 2020 | 19 | 0.170 |
Why?
|
| Precision Medicine | 1 | 2020 | 14 | 0.170 |
Why?
|
| Epilepsy | 1 | 2021 | 34 | 0.170 |
Why?
|
| Recurrence | 1 | 2020 | 26 | 0.170 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 5 | 0.170 |
Why?
|
| Stroke Volume | 1 | 2020 | 13 | 0.160 |
Why?
|
| Heart Rate | 1 | 2020 | 43 | 0.160 |
Why?
|
| Homeostasis | 1 | 2019 | 30 | 0.160 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 19 | 0.160 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2019 | 37 | 0.150 |
Why?
|
| Survival Analysis | 1 | 2018 | 15 | 0.150 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 30 | 0.150 |
Why?
|
| Statistics, Nonparametric | 1 | 2018 | 7 | 0.140 |
Why?
|
| Age Factors | 1 | 2018 | 75 | 0.140 |
Why?
|
| Ophthalmoplegia | 1 | 2017 | 1 | 0.140 |
Why?
|
| Vertebrobasilar Insufficiency | 1 | 2017 | 1 | 0.140 |
Why?
|
| Brain Infarction | 1 | 2017 | 1 | 0.140 |
Why?
|
| Intracranial Thrombosis | 1 | 2017 | 1 | 0.140 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2017 | 1 | 0.140 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 350 | 0.130 |
Why?
|
| Alkalosis, Respiratory | 1 | 2016 | 1 | 0.130 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2016 | 1 | 0.130 |
Why?
|
| Brain Stem | 1 | 2016 | 4 | 0.130 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2015 | 1 | 0.120 |
Why?
|
| Famous Persons | 1 | 2015 | 1 | 0.120 |
Why?
|
| Craniocerebral Trauma | 1 | 2015 | 2 | 0.120 |
Why?
|
| Culture | 1 | 2015 | 9 | 0.120 |
Why?
|
| United States | 1 | 2018 | 521 | 0.120 |
Why?
|
| Mental Disorders | 1 | 2015 | 52 | 0.110 |
Why?
|
| Time Factors | 2 | 2024 | 176 | 0.100 |
Why?
|
| Drainage | 2 | 2022 | 2 | 0.090 |
Why?
|
| Multimorbidity | 1 | 2025 | 4 | 0.060 |
Why?
|
| Endovascular Procedures | 1 | 2024 | 1 | 0.060 |
Why?
|
| Prevalence | 1 | 2025 | 72 | 0.060 |
Why?
|
| Reference Standards | 1 | 2023 | 13 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2023 | 8 | 0.050 |
Why?
|
| Consensus | 1 | 2023 | 14 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2023 | 20 | 0.050 |
Why?
|
| Aspirin | 1 | 2023 | 4 | 0.050 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 18 | 0.050 |
Why?
|
| Drug Prescriptions | 1 | 2023 | 26 | 0.050 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2023 | 6 | 0.050 |
Why?
|
| Electrophysiology | 1 | 2023 | 23 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2023 | 26 | 0.050 |
Why?
|
| Puerto Rico | 1 | 2023 | 5 | 0.050 |
Why?
|
| Research Design | 1 | 2023 | 35 | 0.050 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2023 | 1 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2023 | 4 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 39 | 0.050 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2022 | 1 | 0.050 |
Why?
|
| Cerebrospinal Fluid Leak | 1 | 2022 | 1 | 0.050 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2022 | 10 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2022 | 96 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 277 | 0.050 |
Why?
|
| Death | 1 | 2021 | 2 | 0.050 |
Why?
|
| Needs Assessment | 1 | 2021 | 3 | 0.040 |
Why?
|
| Patient Positioning | 1 | 2021 | 2 | 0.040 |
Why?
|
| Scalp | 1 | 2021 | 10 | 0.040 |
Why?
|
| Depression | 1 | 2023 | 133 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2021 | 4 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 35 | 0.040 |
Why?
|
| Adolescent | 1 | 2025 | 806 | 0.040 |
Why?
|
| Logistic Models | 1 | 2021 | 69 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2021 | 49 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 250 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 136 | 0.040 |
Why?
|
| Child | 1 | 2023 | 657 | 0.040 |
Why?
|
| Troponin I | 1 | 2020 | 2 | 0.040 |
Why?
|
| Echocardiography | 1 | 2020 | 10 | 0.040 |
Why?
|
| Anesthetics | 1 | 2019 | 2 | 0.040 |
Why?
|
| Electrocardiography | 1 | 2020 | 14 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2019 | 7 | 0.040 |
Why?
|
| Artifacts | 1 | 2019 | 12 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 183 | 0.040 |
Why?
|
| Cranial Nerve Diseases | 1 | 2017 | 1 | 0.040 |
Why?
|
| Acute Disease | 1 | 2017 | 9 | 0.040 |
Why?
|
| Intracranial Aneurysm | 1 | 2015 | 2 | 0.030 |
Why?
|
| Vasoconstrictor Agents | 1 | 2015 | 6 | 0.030 |
Why?
|
| Americas | 1 | 2015 | 1 | 0.030 |
Why?
|
| Videodisc Recording | 1 | 2015 | 1 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 97 | 0.030 |
Why?
|
| History, 19th Century | 1 | 2015 | 8 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2015 | 13 | 0.030 |
Why?
|
| Photography | 1 | 2015 | 8 | 0.030 |
Why?
|